

Creso Pharma Ltd

18:18 26 Oct 2020

Creso Pharma's Canadian subsidiary Mernova receives third purchase order from NSLC

Creso Pharma Limited's (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) wholly-owned Canadian subsidiary, Mernova Medicinal Inc, a licensed producer in Nova Scotia, has received and delivered its third purchase order from the Nova Scotia Liquor Corporation (NSLC).

The third purchase order is for 20 cases of Mernova's 'Mimosa' (15-20% THC, less than 1% CBD) strain, which is Mernova's value brand now launched under the Ritual Green brand.

Introduction of the strain will allow Mernova to pursue a much larger addressable market, targeting consumers who are seeking premium quality at a more reasonable price point.

Further orders to be finalised

Mernova managing director Jack Yu said: "Securing this additional purchase order from the NSLC is a significant achievement, and further validates the success of the recent Ritual Green product launch.

"Our products continue to garner very positive feedback from customers and we are confident that the Mimosa strain will unlock a large portion of the market that we can capitalise on in the near term.

"We look forward to updating shareholders on progress in Nova Scotia, additional strain launches under the Ritual Green product range, and further orders to be finalised in the near term."

Confirms success of Ritual Green brand

The order is the third from NSLC in the last four weeks, with the two previous orders for its premium strains, HPG13 (20-25% THC, less than 1% CBD), and Lemon Haze (20-25% THC, less than 1% CBD) continuing to sell well.

Creso is very confident that it will continue to receive purchase orders from NSLC for its Mimosa and premium quality strains.

This will allow the company to build on the around C\$320,000 in revenue it has generated in the last month from the NSLC.

Mernova's Ritual Green products are sold through NSLC stores and e-commerce platform.


The additional purchase order serves as further confirmation of the success of the Ritual Green brand of high-quality cannabis products in the rapidly growing Canadian retail recreational market.

Mernova continues to make significant inroads into the Nova Scotia recreational market, with its diverse products offering premium quality at a competitive price point.

Price: 0.21

Market Cap: \$198.73 m

1 Year Share Price Graph



Share Information

Code: CPH

Listing: ASX

52 week High Low
0.47 0.024

Sector: Cannabis

Website: cresopharma.com

Company Synopsis:

Creso Pharma Limited (ASX:CPH, FRA:1X8 OTCMKTS:COPHF) brings the best of cannabis to better the lives of people and animals.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).